natgillin/translations-raw huggingface dataset:
However, in view of the well established use of the substance in these species and the fact that there was no new information indicating any new risk associated with the use of colistin in calves and lambs in relation to lack of efficacy or human health the Committee considered that the use of colistin in calves and lambs for the treatment of gastrointestinal infections caused by non-invasive E. coli can be maintained. 
Kljub temu z vidika dobro uveljavljene uporabe snovi pri teh živalskih vrstah in dejstva, da ni bilo novih informacij, ki bi kazale nova tveganja, povezana z uporabo kolistina pri teletih in jagnjetih v zvezi z nezadostno učinkovitostjo ali zdravjem ljudi, je Odbor menil, da se lahko uporaba kolistina pri teletih in jagnjetih za zdravljenje okužb prebavil zaradi neinvazivnih sevov E. coli nadaljuje.
With regard to treatment of Salmonella spp. 
V okviru tega postopka v podporo indikacije zdravljenja okužb zaradi Salmonella spp.
These studies provide sufficient support for the treatment of colibacilosis in chickens although the correspondence between the in-feed doses used in these studies and the dose recommended for most products within this referral (75 000 IU colistin per kg body weight once daily for 3 days) was not fully justified. 
Te študije zadostno podpirajo zdravljenje kolibaciloze pri piščancih, čeprav zveza med odmerki v krmi v teh študijah in priporočenimi odmerki za večino zdravil v napotitvi (75 000 i.e. kolistina na kg telesne mase enkrat dnevno 3 dni) ni popolnoma utemeljena.
SCIENTIFIC CONCLUSIONS AND GROUNDS FOR AMENDMENT OF THE SUMMARY OF PRODUCT CHARACTERISTICS 
ZNANSTVENI ZAKLJUČKI IN PODLAGA ZA DOPOLNILO POVZETKA GLAVNIH ZNAČILNOSTI ZDRAVILA
5 Chindiei , sector 4 040185 Bucharest ROMANIA 
040185 Bucharest ROMUNIJA
• the CVMP considered that the Applicants/Marketing Authorisation Holders did not provide any data or argumentation in support of a claim “…for treatment of gastrointestinal infections caused by Salmonella spp…” in calves, lambs, pigs or poultry. 
• CVMP je menil, da predlagatelji/imetniki dovoljenja za promet z zdravilom niso predložili nobenih podatkov ali argumentov v podporo trditvi „…za zdravljenje okužb prebavil zaradi salmonele…“ pri teletih, jagnjetih, prašičih in perutnini.
In the absence of any such data it is considered that this use may constitute a risk to public and animal health as treatment might make the bacteria difficult to detect without completely eliminating the infection/colonisation and therefore result in persistence of zoonotic organisms in treated animals and in the environment and delays in effective elimination. 
Zaradi odsotnosti kakršnih koli takšnih podatkov se šteje, da taka raba lahko pomeni tveganje za javno zdravje in zdravje živali, saj zdravljenje morda oteži odkrivanje bakterije, hkrati pa okužbe/kolonizacije ne odpravi popolnoma, zato povzroči obstojnost zoonotskih organizmov v zdravljenih živalih in v okolju ter odloži učinkovito odstranitev.
The extensive MIC data presented by the Applicants/Marketing Authorisation Holders covering the period during which colistin sulfate has been in clinical use indicates quite clearly that resistance development was not an issue of concern for this substance. 
Predlagatelji/imetniki dovoljenja za promet z zdravilom so predložili obsežne podatke o MIK, ki zajemajo obdobje klinične uporabe kolistinijevega sulfata in jasno kažejo, da pri tej učinkovini pojav odpornosti ni zadržek.
This group of antibiotics has a polypeptide structure, with mainly bactericide activity and a medium antibacterial spectrum, which covers gram-negative microorganisms only. 
Njihov protibakterijski spekter je srednje širok in zajema le gramnegativne mikroorganizme.
For 3 consecutive days. 
TM/dan 3 zaporedne dni
4.9 Amounts to be administered and administration route To be administered orally. 
4.9 Odmerjanje in pot uporabe Zdravilo se daje peroralno.
Considering the general knowledge that the substance is poorly absorbed from the gastro-intestinal tract the Committee considered that the withdrawal period of 1 day as recommended for calves, pigs and chicken can also be supported for lambs and poultry species other than chickens. 
Odbor je ob upoštevanju splošnega znanja, da se snov slabo absorbira iz prebavil, menil, da se lahko karenca 1 dan, ki je priporočena za teleta, prašiče in piščance, podpre tudi za jagnjeta in za drugo perutnino kot piščance.
Furthermore there is no new information indicating any new risk associated with the use of colistin in calves and lambs in relation to lack of efficacy or emerging resistance relevant to public or animal health. 
Poleg tega ni novih informacij, ki bi kazale na nova tveganja v povezavi z rabo kolistina pri teletih in jagnjetih zaradi zmanjšane učinkovitosti ali porajanja odpornosti, ki bi bila pomembna za javno zdravje in zdravje živali.
1 day 
1 dan
Complete or partial lack of efficacy can result in persistence of zoonotic organisms in treated animals (and in the environment) and delay effective elimination of Salmonella due to treatment failure. 
Popolna ali delna neučinkovitost lahko povzroči obstojnost zoonotskih organizmov v zdravljenih živalih (in v okolju) ter odloži učinkovito odstranitev salmonele zaradi neuspešnega zdravljenja.
The United Kingdom expressed concerns that differences in the posology and withdrawal periods established across the European Union for veterinary medicinal formulations containing colistin at 2 000 000 IU/ml and intended for administration in drinking water to any food producing species may present a potential serious risk to public and animal health. 
Združeno kraljestvo je izrazilo zadržke, da razlike v odmerjanju in karencah, ki so v veljavi v Evropski uniji za formulacije zdravil za uporabo v veterinarski medicini, ki vsebujejo 2 000 000 i.e. kolistina/ml in so namenjene dajanju s pitno vodo živalskim vrstam za prehrano ljudi, lahko pomenijo možno resno tveganje za javno zdravje in zdravje živali.
DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION To be administered orally. 
ODMERKI ZA POSAMEZNE ŽIVALSKE VRSTE TER POT(I) IN NAČIN UPORABE ZDRAVILA Zdravilo se daje peroralno.
Concentrate for Oral Solution for use in drinking water for Cattle, Sheep, Swine and Chickens 
Concentrate for Oral Solution for use in drinking water for Cattle, Sheep, Swine and Chickens kolistin (v obliki sulfata)
With regard to gastrointestinal infections caused by non-invasive E. coli in calves and lambs the data submitted to support the indication were limited. 
V zvezi z okužbami prebavil z neinvazivnimi sevi E. coli pri teletih in jagnjetih je podatkov, ki so bili predloženi v podporo indikaciji, malo.
The dose currently recommended in all products authorised for calves and lambs is a harmonised dose of 100 000 IU colistin per kg body weight daily. 
Trenutno priporočeni odmerek vseh zdravil, odobrenih za teleta in jagnjeta, je usklajeni odmerek 100 000 i.e. kolistina na kg telesne mase dnevno.
49500 Segré Cedex FRANCE 
49500 Segré Cedex FRANCIJA
• the CVMP considered that colistin administered orally has been used to treat gastrointestinal infections caused by non-invasive E. coli infections in calves, lambs, pigs and poultry during decades. 
• CVMP je menil, da se je kolistin že več desetletij uporabljal peroralno za zdravljenje okužb prebavil, ki jih povzročajo neinvazivni sevi E. coli pri teletih, jagnjetih, prašičih in perutnini.
In view of the residue data submitted in support of the withdrawal periods in calves, pigs and chickens, and general knowledge that the substance is poorly absorbed from the gastrointestinal tract, the Committee considered that the same withdrawal period of 1 day could be recommended for these animal species. 
Odbor je z vidika predloženih podatkov o ostankih pri teletih, prašičih in piščancih ter splošnega vedenja, da se snov slabo absorbira iz prebavil, menil, da se lahko enaka karenca 1 dan priporoči tudi za omenjene živalske vrste.
In the submitted Periodic Safety Update Reports neither lack of efficacy nor emerging resistance development has been reported for the approved indications in any of the approved target species; 
V predloženih rednih posodobljenih poročilih o varnosti zdravil za predlagane indikacije pri nobeni odobreni ciljni živalski vrsti niso poročali o neučinkovitost ali o porajajočem se pojavu odpornosti;
the CVMP has recommended the variation of the Marketing Authorisations and amendments of the relevant sections of the Summary of Product Characteristics, labelling and package leaflet and where applicable as set out in Annex III of the Opinion for the veterinary medicinal formulations containing colistin at 2 000 000 IU/ml and intended for administration in drinking water to any food producing species as referred in Annex I of the Opinion. 
je CVMP priporočil spremembo dovoljenj za promet z zdravilom in dopolnitev zadevnih poglavij povzetka glavnih značilnosti zdravila, označevanja in navodila za uporabo ter kadar je to ustrezno, kakor je določeno v Dodatku III mnenja za formulacije zdravil za uporabo v veterinarski medicini, ki vsebujejo 2 000 000 i.e. kolistina/ml in so namenjena dajanju v pitno vodo živalskim vrstam za proizvodnjo živil, kakor je opisano v Dodatku I mnenja.
Colivet 2 000 000 UI /ml, concentrate for oral solution for pigs and birds 
Colivet 2 000 000 UI /ml, concentrate for oral solution for pigs and birds koncentrat za peroralno raztopino prašiči domače ptice
Veterinary medicinal formulations containing colistin sulfate at 2 000 000 IU/ml and intended for administration via drinking water to calves, pigs, lambs and poultry are used for the treatment of infections of the gastrointestinal tract caused by Escherichia coli and Salmonella spp susceptible to colistin. 
Formulacije zdravil za uporabo v veterinarski medicini, ki vsebujejo kolistinijev sulfat v koncentraciji 2 000 000 i.e./ml in so namenjene dajanju teletom, prašičem, jagnjetom in perutnini s pitno vodo, se uporabljajo za zdravljenje okužb prebavil z bakterijami Escherichia coli in Salmonella spp, ki so občutljive za kolistin.
Complete or partial lack of efficacy can result in persistence of zoonotic organisms in treated animals and in the environment and delays in effective elimination due to treatment failure. 
Popolna ali delna neučinkovitost lahko povzroči obstojnost zoonotskih organizmov v zdravljenih živalih in v okolju ter odloži učinkovito odstranitev zaradi neuspešnega zdravljenja.
Consequently the benefit-risk balance for colistin was considered negative for treatment of gastrointestinal infections cased by Salmonella spp in calves, lambs, pigs and poultry. 
Posledično se razmerje med koristmi in tveganji za kolistin šteje za negativno za zdravljenje okužb prebavil, ki jih povzročajo salmonele pri teletih, jagnjetih, prašičih in perutnini.
Although the quality of the data provided was considered to be poor and in some cases lacking, and so failed to support some of the indications claimed, the Committee considered that there was sufficient documented evidence in support of efficacy of colistin sulfate when used in pigs for the treatment of gastrointestinal infections caused by non-invasive E. coli, susceptible to colistin, at dose of 100 000 IU colistin per kg body weight daily for 3-5 consecutive days. 
Čeprav so se predloženi podatki o kakovosti šteli za slabe in v določenih primerih pomanjkljivi ter zato ni bilo mogoče podpreti določenih predlaganih indikacij, je Odbor menil, da je bilo zadosti dokumentiranih dokazov v podporo učinkovitosti kolistinijevega sulfata za uporabo pri prašičih za zdravljenje okužb prebavil, ki jih povzročajo neinvazivni sevi E. coli, občutljivi za kolistin, z odmerkom 100 000 i.e. kolistina na kg telesne mase dnevno 3-5 zaporednih dni.
OVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF VETERINARY MEDICINAL FORMULATIONS CONTAINING COLISTIN SULFATE AT 2 000 000 IU/ML AND INTENDED FOR ADMINISTRATION VIA DRINKING WATER TO CALVES, LAMBS, PIGS AND POULTRY SPECIES 
SKUPNI POVZETEK ZNANSTVENEGA VREDNOTENJA FORMULACIJ ZDRAVIL ZA UPORABO V VETERINARSKI MEDICINI, KI VSEBUJEJO KOLISTINIJEV SULFAT V KONCENTRACIJI 2 000 000 I.E./ML IN SO NAMENJENE DAJANJU TELETOM, JAGNJETOM, PRAŠIČEM IN PERUTNINI S PITNO VODO
No residue depletion studies were provided for lambs and for poultry species other than chickens. 
Študije za jagnjeta in za drugo perutnino kot piščance niso bile predložene.
The use of colistin sulfate for the treatment non-invasive E. coli in calves and lambs is considered wellestablished. 
Uporaba kolistinijevega sulfata za zdravljenje okužb z neinvazivnimi sevi E. coli pri teletih in jagnjetih se šteje za dobro uveljavljeno.
The Committee considered that the absence of any data or argumentation from the Applicants/Marketing Authorisation Holders in support of a claim for treatment of Salmonella may constitute a risk to public and animal health as treatment might make the bacteria difficult to detect without completely eliminating the infection/colonisation. 
Odbor je menil, da odsotnost kakršnih koli podatkov ali argumentov s strani predlagateljev/imetnikov dovoljenja za promet z zdravilom v podporo trditev glede zdravljenja okužb s salmonelo lahko pomeni tveganje za javno zdravje in zdravje živali, saj zdravljenje morda oteži odkrivanje bakterije, hkrati pa okužbe/kolonizacije ne odpravi popolnoma.
Poultry For three consecutive days in drinking water 
Colibird koncentrat za peroralno raztopino perutnina tri zaporedne dni v pitno vodo
No residue data were available with regard to lambs and poultry species other than chickens. 
Podatki o ostankih za jagnjeta in perutnino (razen za piščance) niso bili predloženi.
The submitted residue depletion studies were reviewed and based on the recommended posology for cattle (100 000 IU colistin per kg body weight daily for 3-5 consecutive days) and the proposed harmonised posology for pigs and poultry (100 000 IU colistin per kg body weight daily for pigs and 75 000 IU colistin per kg body weight daily in poultry for 3-5 days) the withdrawal periods for calves, pigs and chickens were recalculated using the alternative method 
Predložene študije izločanja ostankov so bile pregledane, na podlagi priporočenega odmerjanja za govedo (100 000 i.e. kolistina na kg telesne mase 3-5 zaporednih dni) in predlaganega usklajenega odmerjanja za prašiče in perutnino (100 000 i.e. kolistina na kg telesne mase dnevno za prašiče in 75 000 i.e. kolistina na kg telesne mase dnevno za perutnino 3-5 dni) pa so bile z drugo metodo2 znova izračunane karence za teleta, prašiče in piščance.
ANNEX III AMENDMENT TO THE SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET 
DODATEK III DOPOLNILO POVZETKA GLAVNIH ZNAČILNOSTI ZDRAVILA, OZNAČEVANJA IN NAVODILA ZA UPORABO
Twice daily for five consecutive days (via drinking water or direct oral administration) 
MIU/ml koncentrat za peroralno raztopino prašiči dvakrat dnevno pet zaporednih dni (s pitno vodo ali neposrednim peroralnim dajanjem)
By contrast, the CVMP considered that the absence of any data or argumentation from the Applicants/Marketing Authorisation Holders in support of a claim “…for treatment of gastrointestinal infections caused by Salmonella spp…” may constitute a risk to public and animal health as treatment might make the bacteria difficult to detect without completely eliminating the infection/colonisation. 
Vendar pa je CVMP menil, da odsotnost kakršnih koli podatkov ali argumentov s strani predlagateljev/imetnikov dovoljenja za promet z zdravilom v podporo trditvi „…za zdravljenje okužb prebavil zaradi salmonele…“ lahko pomeni tveganje za javno zdravje in zdravje živali, saj zdravljenje morda oteži odkrivanje bakterije, hkrati pa okužbe/kolonizacije ne odpravi popolnoma.
Consequently the benefit-risk balance for colistin was considered positive for treatment of gastrointestinal infections caused non-invasive E. coli infections in calves and lambs with the recommended dose of 100 000 IUper kg body weight daily. 
Posledično se razmerje med koristmi in tveganji za kolistin šteje za pozitivno za zdravljenje okužb prebavil, ki jih povzročajo neinvazivni sevi E. coli pri teletih in jagnjetih, s priporočenim odmerkom 100 000 i.e. na kg telesne mase dnevno.
Having considered the residue depletion data submitted by the Applicants/Marketing Authorisation Holders, a withdrawal period of one day for edible tissues and offal from calves, pigs and chickens and zero days for eggs were considered adequate. 
Ob upoštevanju podatkov o izločanju ostankov, ki so jih predložili predlagatelji/imetniki dovoljenja za promet z zdravilom, so se za utemeljene štele karenca en dan za užitna tkiva in drobovino telet, prašičev in piščancev ter karenca nič dni za jajca.
However, as colistin has been approved for decades and resistance has remained low to date, in CVMP's view there was sufficient information available to conclude that resistance was not likely to be an emerging issue. 
Vendar je bil kolistin odobren že več desetletij, odpornost pa je do danes ostala na nizki ravni.
There was also sufficient documented evidence in support of efficacy of colistin sulfate when used in poultry for the treatment of gastrointestinal infections caused by non-invasive E. coli, susceptible to colistin, at a daily dose of 75 000 IU colistin per kg body weight daily for 3-5 consecutive days. 
Bilo je tudi zadosti dokumentiranih dokazov v podporo učinkovitosti kolistinijevega sulfata pri perutnini za zdravljenje okužb prebavil, ki jih povzročajo neinvazivni sevi E. coli, občutljivi za kolistin, če se daje dnevni odmerek 75 000 i.e. kolistina na kg telesne mase dnevno 3-5 zaporednih dni.
infection in calves, lambs, pigs and poultry, no or very limited clinical data was presented to support this indication currently approved for the products within the scope of this procedure. 
pri teletih, jagnjetih, prašičih in perutnini s trenutno odobrenimi zdravili je bilo predloženo zelo malo podatkov ali pa ti sploh niso bili predloženi.
In summary the CVMP considered that there was sufficient information to support the treatment of gastrointestinal infections caused by non-invasive E. coli susceptible to colistin, when administered at dose of 100 000 IU colistin per kg body weight daily for calves, lambs, pigs and 75 000 IU colistin per kg body weight daily in poultry for 3-5 consecutive days. 
Če povzamemo, je CVMP menil, da je zadosti informacij v podporo zdravljenja okužb prebavil, ki jih povzročajo neinvazivni sevi E. coli, občutljivi za kolistin, če se daje odmerek 100 000 i.e. kolistina na kg telesne mase dnevno za teleta, jagnjeta, prašiče in 75 000 i.e. kolistina na kg telesne mase dnevno za perutnino 3-5 zaporednih dni.
Consequently the benefit-risk balance for colistin was considered positive for treatment of gastrointestinal infections caused by non-invasive E. coli in pigs and poultry when used with the posologies mentioned. 
Posledično se razmerje med koristmi in tveganji za kolistin šteje za pozitivnega za zdravljenje okužb prebavil, ki jih povzročajo neinvazivni sevi E. coli pri prašičih in perutnini, če se uporablja omenjeno odmerjanje.
08503 GURB - VIC (Barcelona) Spain 
08503 GURB - VIC (Barcelona) ŠPANIJA
Pigs: 5 days Poultry: 3 days Eggs: do not use in animals from which eggs are produced for human consumption 
meso in drobovina: prašiči in pitovni piščanci: 2 dni Ni za uporabo pri kokoših v obdobju nesnosti, katerih jajca so namenjena za prehrano ljudi.
Poultry 
VOLAILLES
For calves, lambs and pigs the recommended dose is 100 000 IU of colistin per kilogram body weight daily for 3-5 consecutive days. 
Priporočeni odmerek za teleta, jagnjeta in prašiče je 100 000 i.e. kolistina na kg telesne mase dnevno 3-5 zaporednih dni.
Pigs: 50 000 IU colistin per kg of bodyweight per 12 hrs (i.e. 0.25 ml of product per 10 kg of bodyweight per 12 hrs for 35 days via drinking water or milk replacement). 
prašiči: 50 000 i.e. kolistina na kg telesne mase na 12 ur (tj. 0,25 ml zdravila na 10 kg telesne mase na 12 ur 3-5 dni s pitno vodo ali nadomestkom mleka).
• the CVMP considered that a withdrawal period of one day is sufficient for edible tissues and offal of calves, lambs and pigs when administered with dose of 100 000 IU colistin per kg body weight daily for three to five days; 
• CVMP je menil, da karenca en dan zadostuje za užitna tkiva in drobovino telet, jagnjetov in prašičev, če se daje odmerek 100 000 i.e. kolistina na kg telesne mase dnevno tri do pet dni;
Calves, Pigs and Lambs: 
3 dni teleta, jagnjeta, prašiči:
INDICATION(S) Treatment of gastrointestinal infections caused by non-invasive E. coli susceptible to colistin. 
INDIKACIJA(E) Zdravljenje okužb prebavil z neinvazivnimi sevi E. coli, ki so občutljivi za kolistin.
• the CVMP considered that a withdrawal period of one day is sufficient for edible tissues and offal of poultry and zero days for eggs when administered at a dose of 75 000 IU colistin per kg body weight daily for three to five consecutive days; 
• CVMP je menil, da zadostuje karenca en dan za užitna tkiva in drobovino perutnine ter nič dni za jajca, če se daje odmerek 75 000 i.e. kolistina na kg telesne mase dnevno tri do pet dni;
Meat and offal: 7 days 
meso in drobovina: 7 dni
For poultry the recommended dose is 75 000 IU of colistin per kilogram body weight daily for 3-5 consecutive days. 
Priporočeni odmerek za perutnino je 75 000 i.e. kolistina na kg telesne mase dnevno 3-5 zaporednih dni.
In summary withdrawal periods of one day for edible tissues and offal of calves, pigs and chickens and zero days for eggs are considered justified. 
Na kratko, za utemeljene so se štele karenca en dan za užitna tkiva in drobovino telet, prašičev in piščancev ter karenca nič dni za jajca.
The withdrawal periods established in the current SPCs for these species is 7 days. 
Trenutni povzetki glavnih značilnosti zdravila za omenjene živalske vrste določajo karenco 7 dni.
To support the established withdrawal periods eight residue depletion studies in calves, pigs and chickens were submitted by the Applicant/Marketing Authorisation Holders. 
Predlagatelji/imetniki dovoljenja za promet z zdravilom so v podporo uveljavljenim karencam predložili osem študij izločanja ostankov pri teletih, prašičih in piščancih.
Lamb and poultry other than chicken: 7 days 
jagnjeta in perutnina, z izjemo piščancev: 7 dni jajca: nič dni
Oral solution Pigs Birds (Chicken) 
peroralna raztopina prašiči ptice (piščanci)
Treatment of gastrointestinal infections caused by non-invasive E. coli susceptible to colistin. 
Zdravljenje okužb prebavil z neinvazivnimi sevi E. coli, ki so občutljivi za kolistin.
Meat and offal: Calves: 1 day Lambs: 1 day Pigs: 1 day Poultry: 1 day 
Meso in drobovina: teleta: 1 dan jagnjeta: 1 dan prašiči: 1 dan perutnina: 1 dan
Meat and offals: Porcine, calves, chicken: 1 day 
meso in drobovina: prašiči: 1 dan piščanci in kokoši nesnice: 1 dan
Calves Lambs Pigs Poultry 
peroralna raztopina teleta jagnjeta prašiči perutnina
Poultry: meat and eggs: 1 day 
meso: 1 dan jajca: 1 dan
Current SPCs establish withdrawal periods of 7 days for these species. 
Trenutni povzetki glavnih značilnosti zdravil za omenjene živalske vrste določajo karenco 7 dni.
Fattening pigs: 2 days. 
prašiči pitanci: 2 dni pitovni piščanci: 7 dni
However, oral colistin could be useful for treating non-invasive E. coli infection in these species and the effect of treatment is easily detected in clinical practice. 
E. coli pri omenjenih živalskih vrstah, učinek zdravljenja pa je v klinični praksi enostavno določati.
Broilers: 75 000 IU colistin per kg of bodyweight (i.e. 0.37 ml of product per 10 kg of bodyweight per day for 3-5 days via drinking water) 
dnevno, peroralno pitovni piščanci: 75 000 i.e. kolistina na kg telesne mase (tj. 0,37 ml zdravila na 10 kg telesne mase na dan 3-5 dni s pitno vodo)
colistin /1 kg b.w./day for 3 - 5 days, (0,37 ml of product /10 kg b.w.twice daily for 3 - 5 days Pigs: 50000 I.U colistin /1 kg b.w./day for 3 - 5 days, (0,25 ml of product/10 kg b.w. 
Piščanci: 75 000 i.e. kolistina /1 kg TM/dan 3-5 dni (0,37 ml zdravila/10 kg TM dvakrat dnevno 3-5 dni prašiči: 50 000 i.e. kolistina/1 kg TM/dan 3-5 dni (0,25 ml zdravila/10 kg TM dvakrat dnevno 3-5 dni meso in drobovina: 1 dan jajca: 1 dan